

Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]

https://marketpublishers.com/r/T897589A4C2EN.html

Date: December 2015

Pages: 0

Price: US\$ 995.00 (Single User License)

ID: T897589A4C2EN

Abstracts

Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): the future of inhaled insulin in the light of the licensing agreement termination between Sanofi and MannKind Corp for Afrezza; Sanofi's once-daily fixed-dose combination (FDC), LixiLan (insulin glargine and lixisenatide), and how it compares with Novo Nordik's Xultophy (insulin degludec plus liraglutide); Novo Nordisk's investigational long acting glucagon-like peptide-1(GLP-1) agonist, semaglutide; KOLs provide insight on Eli Lilly's recently launched long acting GLP-1 agonist, Trulicity (dulaglutide) and the potential of GLP-1/insulin combinations and discuss the likely impact of the launch of Eli Lilly's biosimilar insulin glargine (Basaglar/Abasaglar).

Key Questions Answered in this Update Bulletin:

What do KOLs think about the future of inhaled insulin following the termination of Sanofi's licensing agreement with MannKind for Afrezza?

What are KOLs opinions of pipeline long-acting injectable GLP-1 agonists, Eli Lilly's Trulicity (dulaglutide) and Novo Nordisk's Phase III product, semaglutide?

What factors will drive the uptake of injectable GLP-1 antagonists as greater choice within this therapy class emerges, and what barriers will this class continue to face?

What concerns do KOLs have Sanofi's LixiLan (insulin glargine and the GLP-1, lixisenatide fixed dose combination)?

Where are the potential opportunities for basal insulin/GLP-1 combinations and what are the critical strategic considerations?



How is Eli Lilly's Basaglar/Abasaglar likely to impact on the use of current basal insulins such as Sanofi's Lantus, Novo Nordisk's Tresiba (insulin degludec) and Sanofi's Toujeo?

Update Bulletins include expert insight and analysis based on FirstWord analyst reengagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.



I would like to order

Product name: Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]
Product link: https://marketpublishers.com/r/T897589A4C2EN.html

Price: US\$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/T897589A4C2EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| Email: | |
|---------------|---------------------------|
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970